SCHEDULE: Dauntless Investment Group Discloses 6.3% Stake in OKYO Pharma

Dauntless Investment Group, LLC has reported a 6.3% passive beneficial ownership stake in OKYO Pharma Ltd, totaling 2,422,048 common shares.

Summary

• Dauntless Investment Group, LLC reported beneficial ownership of 2,422,048 common shares in OKYO Pharma Ltd.
• This represents 6.3% of OKYO Pharma Ltd's common stock.
• The filing indicates Dauntless Investment Group, LLC is a Single Family Office/Passive Investor.
• Dauntless Investment Group, LLC holds sole dispositive power over 433,604 shares and shared dispositive power over 1,988,444 shares.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a substantial passive investment by Dauntless Investment Group, LLC in OKYO Pharma Ltd, which can be viewed as a positive signal of investor confidence in the company's long-term value, without implying any intent to influence control.

Positives

• A significant 6.3% stake by Dauntless Investment Group, LLC, a passive investor, could signal confidence in OKYO Pharma Ltd's long-term prospects.

Future Outlook

NA

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an investment group may instill confidence among existing and potential shareholders, suggesting a belief in the company's value.

Key Dates

Keywords

OKYO Pharma Ltd, Dauntless Investment Group, beneficial ownership, Schedule 13G, passive investor, common stock, equity stake